[Active immunotherapy for breast cancer]
Fernández Zurbarán M, Llanos Méndez A, Baños Álvarez E
Record ID 32013000750
Spanish
Authors' objectives:
We conducted a systematic review with the objective of assessing the safety and the immunogenicity of active immunotherapy for breast cancer, recovering an emerging technology briefing, 4 randomised clinical trials (RCT), and 3 case-series
Authors' recommendations:
The outcomes of the RCT showed no significant differences between the intervention and control groups in terms of overall survival and progression-free survival. The median survival times reported by Miles et al. (the largest simple size trial) were 23.1 months in the treatment group and 22.3 months in the control group (p= 0,916). The patients from case-series did not achieve complete or partial response by RECIST criteria.
Details
Project Status:
Completed
Year Published:
2013
URL for published report:
https://www.aetsa.org/download/publicaciones/antiguas/AETSA_17_5_Vacuna_CaMama.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Spain
MeSH Terms
- Breast Neoplasms
Contact
Organisation Name:
Andalusian Health Technology Assessment Area
Contact Address:
Area de Evaluacion de Tecnologias Sanitarias Sanitarias de Andalucia (AETSA) Avda. Innovación, s/n Edificio Arena 1. Sevilla (Spain) Tel. +34 955 006 309
Contact Name:
aetsa.csalud@juntadeandalucia.es
Contact Email:
aetsa.csalud@juntadeandalucia.es
Copyright:
Andalusian Agency for Health Technology Assessment (AETSA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.